Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
Halozyme views its drug delivery technology for biologic medicines as complementary to Evotec’s biologic drug manufacturing capabilities. But according to Halozyme, Evotec was unwilling to engage in any merger discussions.
